T. Rowe Price Associates
ANIK icon

T. Rowe Price Associates’s Anika Therapeutics ANIK Stock Holding History

T. Rowe Price Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,998
Closed -$215K – 2934
2022
Q3 		$215K Buy
+8,998
New +$207K ﹤0.01% 2517
2022
Q1 		– Sell
-7,659
Closed -$274K – 2977
2021
Q4 		$274K Buy
7,659
+435
+6% +$17.4K ﹤0.01% 2629
2021
Q3 		$307K Buy
7,224
+27
+0.4% +$1.11K ﹤0.01% 2569
2021
Q2 		$312K Buy
7,197
+708
+11% +$30.2K ﹤0.01% 2584
2021
Q1 		$265K Sell
6,489
-17
-0.3% -$645 ﹤0.01% 2601
2020
Q4 		$294K Sell
6,506
-100
-2% -$3.79K ﹤0.01% 2428
2020
Q3 		$234K Hold
6,606
– – ﹤0.01% 2376
2020
Q2 		$249K Buy
+6,606
New +$218K ﹤0.01% 2300
2020
Q1 		– Sell
-6,445
Closed -$334K – 2513
2019
Q4 		$334K Buy
6,445
+522
+9% +$30.3K ﹤0.01% 2285
2019
Q3 		$325K Sell
5,923
-4,630
-44% -$238K ﹤0.01% 2256
2019
Q2 		$429K Buy
10,553
+20
+0.2% +$729 ﹤0.01% 2171
2019
Q1 		$319K Buy
10,533
+40
+0.4% +$1.37K ﹤0.01% 2272
2018
Q4 		$353K Buy
10,493
+23
+0.2% +$830 ﹤0.01% 2220
2018
Q3 		$442K Buy
10,470
+86
+0.8% +$3.4K ﹤0.01% 2201
2018
Q2 		$332K Buy
+10,384
New +$428K ﹤0.01% 2315
2016
Q3 		– Sell
-5,440
Closed -$292K – 2528
2016
Q2 		$292K Hold
5,440
– – ﹤0.01% 2188
2016
Q1 		$243K Hold
5,440
– – ﹤0.01% 2235
2015
Q4 		$208K Buy
+5,440
New +$208K ﹤0.01% 2293

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

T. Rowe Price Associates's ANIK Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Anika Therapeutics (ANIK) in Q4 2022, closing a stake of 8,998 shares — an estimated $215K sold.

T. Rowe Price Associates first reported a position in ANIK in Q4 2015 and held it in 18 quarters. The position peaked at $442K in Q3 2018. 125 funds tracked by Wall St. Rank hold ANIK as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Anika Therapeutics position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 8,998 Anika Therapeutics shares in Q4 2022, an estimated $215K.
  • T. Rowe Price Associates first reported a position in Anika Therapeutics in Q4 2015 and held it in 18 quarters.
  • T. Rowe Price Associates's Anika Therapeutics position peaked at $442K in Q3 2018.
  • 125 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.